BioMarin’s Strong Q1 2025 Performance and Growth Outlook

Biomarin Pharmaceutical Inc. ( (BMRN) ) has released its Q1 earnings. Here is a breakdown of the information Biomarin Pharmaceutical Inc. presented to its investors.

BioMarin Pharmaceutical Inc., a biotechnology company based in San Rafael, California, focuses on developing and commercializing innovative therapies for rare genetic conditions.

In its first-quarter 2025 earnings report, BioMarin announced a total revenue of $745 million, marking a 15% increase year-over-year. The company also reported a significant rise in GAAP diluted earnings per share, which doubled to $0.95, and a 59% increase in non-GAAP diluted EPS to $1.13.

Key financial highlights include a 40% year-over-year revenue growth for VOXZOGO, driven by new patient initiations globally, and an 8% increase in enzyme therapies revenue. The company’s net income surged by 109% to $186 million, attributed to higher gross profit and reduced operating expenses following strategic portfolio adjustments. BioMarin also advanced its clinical pipeline, with positive results from the Phase 3 PALYNZIQ study and the completion of enrollment for VOXZOGO’s hypochondroplasia study.

Looking ahead, BioMarin reaffirms its full-year 2025 guidance, projecting total revenues between $3.1 billion and $3.2 billion. The company anticipates continued growth in its VOXZOGO and enzyme therapies, alongside strategic investments in clinical pipeline development and global expansion initiatives.